Paradigm Biopharmaceuticals share price freefalls 27% following $66m cap raise

Paradigm shares have erased all of last week's gains…

| More on:
A disappointed female investor sits in front of her laptop and puts her hand to her forehead and closes her eyes in disappointment over share price falls

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Paradigm shares sink 27% on the back of the company's latest equity raise
  • Paradigm is seeking to boost its capital to fund its phase 3 clinical program and other activities through to 2024
  • Retail investors can participate in a one for 15 pro-rata non renounceable entitlement offer at $1.30 per share

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is plummeting after coming out of a trading halt this morning.

At the time of writing, the biopharmaceutical company's shares are fetching at $1.45, down 26.95%.

What's driving the Paradigm share price lower?

Investors are scrambling to offload Paradigm shares amid an impending share dilution from the company.

According to its announcement, Paradigm advised it has launched a fully underwritten $66 million capital raise.

This comprises of a $45.7 million institutional placement to domestic and offshore investors and a one for 15 pro-rata non-renounceable entitlement offer of $20.3 million at $1.30 per share.

The company noted the placement received strong participation from domestic and offshore institutional investors. This will result in the issue of approximately 35.1 million Paradigm shares.

The record date for the entitlement offer is on Thursday 18 August 2022.

Eligible shareholders subscribing for their entitlement can also apply for additional shares under a top-up facility. However, this will be capped at 100% of an eligible shareholder's entitlement.

The entitlement offer will result in the issue of approximately 15.6 million shares.

Following completion of the capital raise, the company will have a proforma cash position of $108.5 million. This will provide sufficient cash flow to see through its operations into the 2024 calendar year.

What will the funds be used for?

The monies raised from the capital raise will be used to fund a number of initiatives that include the following:

  • Paradigm's phase 3 clinical program and new drug application (NDA)-related activities;
  • Business development-related activities;
  • Product development-related activities (such as auto-injector); and
  • Working capital.

Paradigm chair Paul Rennie commented:

I would like to thank all institutional Investors who participated in the placement, and I am delighted that all Paradigm shareholders now have the right to also invest under the fully under-written non-renounceable entitlement offer.

Personally, I will be subscribing for $300,000 of new Paradigm stock under the entitlement offer. Having a strong balance sheet is important to Paradigm so we can maintain or accelerate the momentum of our Phase 3 clinical trial. A strong balance sheet is important as we have commercial discussions in the future.

Paradigm share price review

It has been an interesting year for Paradigm shares, treading lower for most of 2022 until recently shooting higher.

The company's share price reached a year-to-date high of $2.17 on 9 August before going into a trading halt the following day.

Based on today's price, Paradigm has a market capitalisation of roughly $332 million, with more than 228 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Capital Raising

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Capital Raising

Why is this ASX 300 stock crashing 18% today?

Let's see what is making investors hit the sell button today.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX All Ords stock sinking 14% on Friday?

Let's see why investors hitting the sell button today.

Read more »

Data Centre Technology
Capital Raising

NextDC share price drops on $750m capital injection for Asian expansion

The data centre operator is raising funds to support its expansion.

Read more »

Kid stacking coins from the jar.
Capital Raising

This ASX 300 stock is rising after completing its next step for Canadian growth

Expanding in Canada could be a patently good idea.

Read more »

Successful group of people applauding in a business meeting and looking very happy.
Capital Raising

Guess which ASX All Ords stock is leaping 9% after raising $60 million

This fast-growing company is maintaining a lean balance sheet while making an accretive acquisition.

Read more »

A robot grimaces and looks alarmed as it sits frozen in ice.
Capital Raising

Up 140% in a month, here's why this high-flying ASX small-cap stock has just been frozen

This ASX robotics company requested a trading halt today.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Capital Raising

DroneShield shares dive 17% amid $120 million for AI ambitions

The counter-drone company plans to lean into AI advancements to secure its 'market leader' status

Read more »

Young girl bored staring out the window at the rain in lockdown.
Capital Raising

Why are DroneShield shares locked down today?

DroneShield is on the hunt for more cash despite having $146 million worth already.

Read more »